ArticleNature medicine2025
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.
Abstract readClinical Trial, Phase I
In one paragraph
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety profiles of CAR-T cell therapy in systematic autoimmune diseases: a systematic review and analysis.Immunologic research · 2026Pooled it
- Mechanism-informed combination therapy and dynamic risk stratification in lupus nephritis: toward durable renal protection.Clinical rheumatology · 2026Review
- Organization from cell to tissue derived delivery systems for immunotherapy.Materials today. Bio · 2026Article
- Beyond Oncology: Exploring the Expanding Role of CAR T Cell Therapy in Autoimmune and Infectious Diseases-A Systematic Review.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Cellular therapies in systemic lupus erythematosus: recent progress and future directions.Clinical rheumatology · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Long-term clinical outcomes and safety of rituximab in refractory neuropsychiatric systemic lupus erythematosus: a real-world single-center study.Clinical rheumatology · 2026Article
- Challenges and opportunities: CAR-T cell therapy in autoimmune diseases.Cell insight · 2026Review
- Resetting autoimmune disease with CAR cell therapies.Nature medicine · 2026Review
- Decoding DNA metabolism and its clinical relevance through the lens of high-throughput sequencing assays.Medical review (2021) · 2026Review
- Roads and detours for CAR T cell therapy in autoimmune diseases.Nature reviews. Drug discovery · 2026Review
- A trial of hypoimmune allogeneic CD19-targeting T cells in refractory systemic lupus erythematosus.Clinical kidney journal · 2026Article
- Review
- The dawn of 'off-the-shelf' B cell-depleting therapies for autoimmune diseases.Nature reviews. Rheumatology · 2026Article
- Research advances and application prospects of CAR-T therapy in the treatment of age-related diseases.Frontiers in immunology · 2026Review
- B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting.Frontiers in immunology · 2026Review
- Advancements and expanding applications of CAR-T cell therapy.Frontiers in immunology · 2026Review
- Refractory lupus nephritis: current Understanding and emerging treatment strategies.Clinical and experimental medicine · 2025Review
- Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease.Biology · 2025Review
- Chimeric antigen receptor (CAR) therapies for precise eradication of pathogenic cells in autoimmunity.Arthritis research & therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors.
Xiaobing Wang *Department of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Yi Zhang *Department of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Huimin Wang *Institute for Immunology and School of Basic Medical Sciences, Tsinghua University, Beijing, China.
Xin Wu *Department of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Chao He *Department of Emergency Intensive Care Unit, Changzheng Hospital, Naval Medical University, Shanghai, China.
Suxian LinRheumatology Department, Wenzhou People's Hospital, Wenzhou, China.
Kun PangUniversity of Chinese Academy of Sciences, Beijing, China.
Yang LiBriSTAR Immunotech Limited, Building 4, Medical and Pharma Tech Center, Life Science Park, Changping, Beijing, China.
Yue ChenInstitute of Genomic Medicine, Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, China.ORCID http://orcid.org/0009-0004-5110-6400
Xiaojing TangDepartment of Nephrology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Xin LiuDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Jiazheng WangDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Songying YeDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Ran YanDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.ORCID http://orcid.org/0009-0005-9442-3083
Tongxiang GuanDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Bing DaiDepartment of Nephrology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Jing LuDepartment of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China.
Haiyan HeDepartment of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China.
Li LinDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Hongjuan LuDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Ting LiDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Ling ZhouDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Lingying YeDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Juan ZhaoDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China.
Yanfang LiuDepartment of Pathology, Changhai Hospital, Naval Medical University, Shanghai, China.ORCID http://orcid.org/0000-0002-2923-0729
Na TaDepartment of Pathology, Changhai Hospital, Naval Medical University, Shanghai, China.
Jun WuDepartment of Nephrology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Wanshi CaiiGeneTech Bioscience Co. Ltd, Beijing, China.
Zhe WanBriSTAR Immunotech Limited, Building 4, Medical and Pharma Tech Center, Life Science Park, Changping, Beijing, China.
Shasha ZhangBriSTAR Immunotech Limited, Building 4, Medical and Pharma Tech Center, Life Science Park, Changping, Beijing, China.
Ruya SunInstitute for Immunology and School of Basic Medical Sciences, Tsinghua University, Beijing, China.
Xueqiang ZhaoInstitute for Immunology and School of Basic Medical Sciences, Tsinghua University, Beijing, China.
Jiasheng WangChangping Laboratory, Beijing, China.
Yong LinDepartment of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Beifang NingDepartment of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Zhengqing ZhaoDepartment of Neurology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Xiaofeng TangDepartment of Blood Center, Changzheng Hospital, Naval Medical University, Shanghai, China.
Juan DuDepartment of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China.ORCID http://orcid.org/0000-0003-2538-4007
Zhiguo MaoDepartment of Nephrology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Yanran HeCommittee on Cancer Biology, The University of Chicago, Chicago, IL, USA.
Hongli ZhengBriSTAR Immunotech Limited, Building 4, Medical and Pharma Tech Center, Life Science Park, Changping, Beijing, China.
Lingyun SunDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Xin LinInstitute for Immunology and School of Basic Medical Sciences, Tsinghua University, Beijing, China.ORCID http://orcid.org/0000-0003-0956-3654
Huji XuDepartment of Rheumatology and Immunology, National key laboratory for immunity and inflammation, Changzheng Hospital, Naval Medical University, Shanghai, China. xuhuji@smmu.edu.cn.ORCID http://orcid.org/0000-0002-8588-118X
Funding
National Natural Science Foundation of China (National Science Foundation of China) 82271816National Natural Science Foundation of China (National Science Foundation of China) 82341212National Science Foundation of China | Key Programme 82320108010
Abstract
Commercial autologous anti-CD19 chimeric antigen receptor-T cell therapies are effective in B cell malignancies and autoimmune diseases but are limited by personalized manufacturing, high costs and the risk from random chimeric antigen receptor insertion into the genome. To overcome these challenges, we developed YTS109, a hypoimmune allogeneic T cell product engineered using CRISPR-Cas9 to knock out TRAC, PD1, HLA-A, HLA-B and CIITA, with a CD19-targeting synthetic TCR and antigen receptor (STAR) precisely integrated into the TRAC locus to enable physiological, TCR-like signaling. As part of a multi-disease cohort trial, this article includes all enrolled five patients with severe, refractory systemic lupus erythematosus (SLE) complicated by lupus nephritis, who received lymphodepletion followed by YTS109 at 3 × 10
Indexed as
Antigens, CD19Lupus Erythematosus, SystemicT-LymphocytesAdultFemaleHumansLupus NephritisMaleMiddle AgedReceptors, Antigen, T-CellTreatment OutcomeYoung AdultAntigens, CD19Receptors, Antigen, T-Cell
Identifiers
PMID
40866583What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.